ESMO 2025 will serve as a global hub where groundbreaking research, innovative treatments, and cross-sector collaboration come together to shape the future of cancer care. Ulla Buhl (CEO) and Peter Buhl (CMO) will attend ESMO 2025 to present a poster on prediction of taxane efficacy in breast cancer patients